The Woburn-based knee repair firm inks a deal with Lonza's Hopkinton, Mass., facility to make the fibroblast growth factor variant for its BioCart knee cartilage repair system.
ProChon Biotech Ltd. inked a deal to have Swiss firm Lonza manufacture a key element of its BioCart knee repair system.
Lonza will make Woburn, Mass.-based ProChon's proprietary fibroblast growth factor variant at its Hopkinton, Mass., plant. The BioCart system, which cultures a healthy sample of knee cartilage and implants it back into the damaged knee, uses the FGF2v product to stimulate cartilage growth on an implant scaffold.
ProChon CEO Patrick O’Donnell said the choice of Lonza's local operation demontrates his company's commitment to creating jobs in the Bay State. As further evidence, O'Donnell cited a separate deal with Averion International Corp. of Southborough to help run clinical trials of the BioCart system.
Basel, Switzerland-based Lonza has operations in Portsmouth, N.H., Rockland, Maine, Pennsylvania, Illinois, Maryland and Minnesota, in addition to its Hopkinton facility.
The BioCart system is in clinical trials in preparation for regulatory approval applications in the U.S. and Europe.
President Barack Obama took to the stump in Ohio to press for the passage of healthcare reform.
Medical device maker Z-Medica of Wallingford, Conn., pledges $25,000 to the Yellow Ribbon program at...
New Haven-based cancer therapy diagnostics firm HistoRx Inc. lands a $1.5 million loan from...
EnteroMedics Inc. is preparing for another clinical trial of its Maestro neurostimulation implant in...